| Publications | PubMed=2469723; DOI=10.4049/jimmunol.142.10.3692
Anichini A., Mazzocchi A., Fossati G., Parmiani G.
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
J. Immunol. 142:3692-3701(1989) PubMed=2776368; DOI=10.1007/BF01753674
Larizza L., Doneda L., Rodolfo M., Fossati G.
High incidence of chromosomal lesions involving C-heterochromatin in four human melanoma lines.
Clin. Exp. Metastasis 7:633-644(1989) PubMed=8459226; DOI=10.1084/jem.177.4.989; PMCID=PMC2190978
Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A., Squarcina P., Herlyn M., Parmiani G.
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
J. Exp. Med. 177:989-998(1993) PubMed=7520026; DOI=10.1002/ijc.2910580413
Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.
Expression of the co-stimulatory molecule B7 on melanoma cells.
Int. J. Cancer 58:527-532(1994) PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#
Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.
Expression of the co-stimulatory molecule CD40 on melanoma cells.
Int. J. Cancer 68:795-801(1996) PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) DOI=10.1007/0-306-46872-7_16
Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.
Melanoma: the Milan melanoma cell lines.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999) PubMed=9973437; DOI=10.4049/jimmunol.162.3.1739
Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L., Ravagnani F., Gallino F., Belli F., Parmiani G.
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
J. Immunol. 162:1739-1748(1999) PubMed=15048078; DOI=10.1038/sj.onc.1207563
Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P.S., Ringner M., Hayward N.K.
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004) PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012) DOI=10.13130/grazia-giulia_phd2016-02-18
Grazia G.
Co-targeting of oncogenic and death receptors pathways in human melanoma: pre-clinical rationale for a pro-apoptotic and anti-angiogenic strategy.
Thesis PhD (2015); Universita degli studi di Milano; Milano; Italy |
|---|
